| Page 1658 | Kisaco Research
 

Warren Bobrow

Author, Mixologist, Barman, Owner, Cocktail Whisperer

Warren Bobrow

Author, Mixologist, Barman, Owner, Cocktail Whisperer

Warren Bobrow

Author, Mixologist, Barman, Owner, Cocktail Whisperer
Sample Attendee List
 

Willem Nissink

Associate Principle Scientist
AstraZeneca

Willem Nissink

Associate Principle Scientist
AstraZeneca

Willem Nissink

Associate Principle Scientist
AstraZeneca
 

Matthias Wittwer

PDM Project Leader
Roche

Matthias Wittwer

PDM Project Leader
Roche

Matthias Wittwer

PDM Project Leader
Roche
 

Simon Bailey

EVP, Head of Drug Discovery
Plexium

As Head of Drug Discovery at Plexium, Simon oversees the company’s efforts to identify novel protein degrader drugs that address significant unmet medical needs. Simon joined Plexium in 2019 bringing more than 25 years’ experience of medicinal chemistry and small molecule drug discovery leadership experience. From 1995-2015, Simon held positions of increasing responsibility at Pfizer including leading the Diabetes and Oncology Medicinal Chemistry Departments. 

Simon Bailey

EVP, Head of Drug Discovery
Plexium

Simon Bailey

EVP, Head of Drug Discovery
Plexium

As Head of Drug Discovery at Plexium, Simon oversees the company’s efforts to identify novel protein degrader drugs that address significant unmet medical needs. Simon joined Plexium in 2019 bringing more than 25 years’ experience of medicinal chemistry and small molecule drug discovery leadership experience. From 1995-2015, Simon held positions of increasing responsibility at Pfizer including leading the Diabetes and Oncology Medicinal Chemistry Departments. 

 

Andy Pike

Senior DMPK Lead
AstraZeneca

Andy Pike

Senior DMPK Lead
AstraZeneca

Andy Pike

Senior DMPK Lead
AstraZeneca
 

Zhengnian Li

PhD, Post-Doctoral Fellow, Laboratory of Dr. Nathanael Gray
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School

Zhengnian Li

PhD, Post-Doctoral Fellow, Laboratory of Dr. Nathanael Gray
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School

Zhengnian Li

PhD, Post-Doctoral Fellow, Laboratory of Dr. Nathanael Gray
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School
 

Gopal Sapkota

Programme Leader in Protein Phosphorylation
University of Dundee

Gopal Sapkota

Programme Leader in Protein Phosphorylation
University of Dundee

Gopal Sapkota

Programme Leader in Protein Phosphorylation
University of Dundee
 

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX
 

Michael Dabrowski

Co-founder & CEO
Pelago Biocsience

Michael Dabrowski, PhD, co-founder and CEO of Pelago Bioscience. Michael began his Drug Discovery career as an industrial Masters- and PhD-student at Novo Nordisk and worked as a postdoc on Type 2 diabetes. He then developed a long career at AstraZeneca: from senior scientist and technology expert, to project and scientific leader and manager.

Michael Dabrowski

Co-founder & CEO
Pelago Biocsience

Michael Dabrowski

Co-founder & CEO
Pelago Biocsience

Michael Dabrowski, PhD, co-founder and CEO of Pelago Bioscience. Michael began his Drug Discovery career as an industrial Masters- and PhD-student at Novo Nordisk and worked as a postdoc on Type 2 diabetes. He then developed a long career at AstraZeneca: from senior scientist and technology expert, to project and scientific leader and manager. Through his diverse career, Michael has built a vast industry network and accumulated experience in Drug Discovery, from active laboratory activity, assay and test development, personnel manager, project management and overall portfolio responsibilities. Michael’s key strengths and experience are in establishing cross functional collaborations and Business Development.